Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novasep Sells TangenX to Repligen | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novasep Sells TangenX to Repligen

Supports strategic plan to focus on core activities

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novasep has sold its U.S. subsidiary, TangenX Technology Corp., to Repligen Corp. for $39.0 million in cash.

In 2006, Novasep acquired a majority stake in TangenX, located in Shrewsbury, MA. The company develops, produces and sells tangential flow filtration (TFF) technologies designed to help biomanufacturers reduce industrial purification costs of biopharmaceuticals. Its single-use TFF cassettes Sius currently has strong sales.

“We are pleased to have finalized this deal with Repligen,” said Novasep chairman and chief executive officer, Dr. Michel Spagnol. “We were the first industrial investor in TangenX and supported the development and the launch of its innovative TFF technology. Repligen’s infrastructure, which is perfectly adapted to the Sius range, will help to develop the product at the pace this technology deserves.”

“For more than three years, Novasep has been pursuing its strategy aimed at refocusing the company on its core activities. This transaction reinforces our capacity to accelerate strategic growth,” he added.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics